NCT06055920
The PEERLESS II Study
Active, Not Recruiting
NAAges 18+InterventionalTreatmentInari Medical
~1,200 participants
Updated 2026-08-06 on ClinicalTrials.gov
What's tested:FlowTriever SystemAnticoagulation Agents
At a glance
Recruiting sites
0 of 77 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Composite clinical endpoint constructed as a win ratio, a hierarchy of the following, which are assessed post-randomization:
Measured over through discharge or 30 days, whichever is sooner / dyspnea at 48 hours
Conditions
Where it's being run
77 sites across 28 statesGermany18
Pennsylvania9
New York6
Texas4
France4
Ohio3
Tennessee3
British Columbia3
Study leadership
- Frances Mae West, MD · PRINCIPAL_INVESTIGATOR · Jefferson Health
- Jay Giri, MD · PRINCIPAL_INVESTIGATOR · Penn Medicine
- Bernhard Gebauer, MD · PRINCIPAL_INVESTIGATOR · Charité University Hospital Berlin
- Felix Mahfoud, MD · PRINCIPAL_INVESTIGATOR · Universitaetsspital Basel
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Composite clinical endpoint constructed as a win ratio, a hierarchy of the following, which are assessed post-randomization:through discharge or 30 days, whichever is sooner / dyspnea at 48 hours
* All-cause mortality by 30 days, or * Clinical deterioration, defined by hemodynamic or respiratory worsening, through discharge or up to 30 days after randomization, whichever is sooner, or * All-cause hospital re-admission by 30 days, or * Bailout therapy, either after a deterioration or after documented failure to progress, through discharge or up to 30 days after randomization, whichever is sooner, or * Change in Dyspnea, by mMRC from Baseline to the 48-hour visit